Immunovia
Logotype for Immunovia

Immunovia (IMMNOV) investor relations material

Immunovia Q4 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Immunovia
Q4 2025 earnings summary24 Feb, 2026

Executive summary

  • Achieved commercial launch of PancreaSure in September 2025 after over two years of development and clinical research, with strong adoption in high-risk surveillance centers and positive reception from the medical community.

  • Published five clinical studies, including pivotal CLARITI and VERIFI validation studies, and received recognition at major scientific conferences.

  • Built strong advocacy among key opinion leaders and high-risk surveillance centers, with early adoption by 12 centers by year-end 2025.

  • Secured $897 Medicare reimbursement rate and raised over 140 million SEK to support launch and clinical studies.

  • Added three strategic account managers to accelerate adoption and integration at key centers.

Financial highlights

  • Q4 2025 net sales were SEK 354,000, mainly from royalty and PancreaSure test revenues, down from SEK 455,000 in Q4 2024.

  • Operating loss for Q4 2025 was SEK 16.4 million, improved from SEK 30.1 million in Q4 2024.

  • Cash burn in Q4 was SEK 6.6 million per month, below guidance, with a year-end cash position of SEK 77.5 million.

  • Rights issue in Q4 2025 raised 100 million SEK (net SEK 69.8 million), extending cash runway through Q3 2026.

  • Cash flow from operating activities improved to -19.8 MSEK in Q4 2025 from -28.3 MSEK in Q4 2024.

Outlook and guidance

  • Expect meaningful revenue from PancreaSure after 2026, with significant ramp-up in 2027.

  • Cash runway secured through Q3 2026 based on current cash balance and cost management.

  • Plan to submit for Medicare coverage in mid-2026, with some Medicare Advantage reimbursement expected in 2026.

  • Initial clinical utility data anticipated in Q2 2026.

  • Additional capital will be needed to fund operations beyond Q3 2026; exploring grants, partnerships, and equity options.

PancreaSure adoption rate and volume trends
Path to Medicare coverage post-Q2 utility data
Strategic partner impact on post-Q3 2026 funding
How will new sales staff accelerate pipeline?
How will clinical utility data secure Medicare coverage?
What is the plan to fund operations beyond Q3 2026?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Immunovia earnings date

Logotype for Immunovia
Q1 20267 May, 2026
Immunovia
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Immunovia earnings date

Logotype for Immunovia
Q1 20267 May, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Immunovia AB, a Swedish diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company was founded in 2007 and is listed on Nasdaq Stockholm First North Premier under the ticker IMMUV. Immunovia focuses on blood markers with an impact on health risk assessment, prevention and drug development. The tests have the potential to significantly improve doctors' possibilities to predict and prevent people from getting ill. The most advanced applications for our tests are for important risk groups such as breast cancer patients, heart attack cases, or diabetes type 2 sufferers. Immunovia AB is headquartered in Lund, Sweden.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage